RA Capital Management

Selected news for the capital firm - RA Capital Management, collected since 11/2017. This capital firm shares healthcare news with OrbiMed, Oncology, Biotech, Biopharma and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 Covid-19 Pill Developer to Spend SPAC IPO Funds on Clinical Trial, Hiring - WSJ The Wall Street Journal ... Foresite Capital. Pardes said it raised $274 million, including $199 million from the SPAC’s trust account and $75 million in the form of a private investment in public equity from Foresite, investment manager RA Capital Management and biotech giant Gilead Sciences Inc., among others.Pardes is one of several drugmakers —alongside Pfizer Inc., Watertown, Mass.-based Enanta Pharmaceuticals Inc. and Japanese drugmaker Shionogi & Co. Ltd.––that are developing ...
1/10/2022 Daiwa Securities Group Inc. Takes Position in Connect Biopharma Holdings Limited (NASDAQ:CNTB) - Ticker Report Ticker Report ... SEC. The institutional investor acquired 6,069 shares of the company’s stock, valued at approximately $147,000.Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CNTB. RA Capital Management L.P. boosted its holdings in shares of Connect Biopharma by 133.7% in the 2nd quarter. RA Capital Management L.P. now owns 6,991,003 shares of the company’s stock valued at $136,534,000 after buying ...
1/10/2022 Daiwa Securities Group Inc. Takes Position in Connect Biopharma Holdings Limited (NASDAQ:CNTB) - Watch List News watchlistnews.com ... disclosure with the Securities & Exchange Commission. The fund bought 6,069 shares of the company’s stock, valued at approximately $147,000.Several other large investors also recently made changes to their positions in the stock. RA Capital Management L.P. boosted its position in shares of Connect Biopharma by 133.7% during the second quarter. RA Capital Management L.P. now owns 6,991,003 shares of the company’s stock valued at $136,534,000 after buying ...
1/7/2022 AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program PR Newswire ... financing is expected to support advancement of AN2's development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).The financing was led by RA Capital Management , and included BVF Partners L.P., Surveyor Capital (a Citadel company), Avidity Partners, Monashee Investment Management, and Hatteras Venture Partners, who joined existing investors to complete this round."We are joined by a top ...
1/7/2022 AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program | News | bakersfield.com bakersfield.com ... financing is expected to support advancement of AN2's development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).The financing was led by RA Capital Management , and included BVF Partners L.P., Surveyor Capital (a Citadel company), Avidity Partners, Monashee Investment Management, and Hatteras Venture Partners, who joined existing investors to complete this round."We are joined by a top ...
1/7/2022 AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program | Business & Finance | citizentribune.com citizentribune.com ... financing is expected to support advancement of AN2's development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).The financing was led by RA Capital Management , and included BVF Partners L.P., Surveyor Capital (a Citadel company), Avidity Partners, Monashee Investment Management, and Hatteras Venture Partners, who joined existing investors to complete this round."We are joined by a top ...
1/7/2022 AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program | Business | The Daily News galvnews.com ... financing is expected to support advancement of AN2's development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).The financing was led by RA Capital Management , and included BVF Partners L.P., Surveyor Capital (a Citadel company), Avidity Partners, Monashee Investment Management, and Hatteras Venture Partners, who joined existing investors to complete this round."We are joined by a top ...
1/4/2022 Deutsche Bank AG Boosts Holdings in Ascendis Pharma A/S (NASDAQ:ASND) - Watch List News watchlistnews.com ... Ascendis Pharma A/S by 57.8% in the second quarter. Invesco Ltd. now owns 1,159,024 shares of the biotechnology company’s stock worth $152,469,000 after buying an additional 424,732 shares during the last quarter. RA Capital Management L.P. increased its stake in shares of Ascendis Pharma A/S by 6.1% in the second quarter. RA Capital Management L.P. now owns 6,806,341 shares of the biotechnology company’s stock worth $895,374,000 ...
12/30/2021 The Most Active Biotech Venture Investors in 2021 preiposwap.com ... and more. But two of those investment firms have emerged as major leaders, not only in the number of biotech funding rounds led, but also in overall dollars invested into the industry. Boston-based RA Capital Management and New York-based OrbiMed ranked first and second, respectively, on the two lists compiled using Crunchbase data. Although the two firms emerged as leaders in the data, they still make up a ...
12/28/2021 Follow the Money: AI-Driven Talent Engagement, Cancer Center Funding, Maternal Health, More bio-itworld.com ... in clinical-grade blood collection technology, announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million. The financing round was led by RA Capital Management and included participation from new investors the D.E. Shaw group, Senvest, InCube, and SVB Innovation Fund, as well as existing investors Foresite Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai, and Merck GHIF ...
12/27/2021 MacroGenics, Inc. (NASDAQ:MGNX) Shares Acquired by WINTON GROUP Ltd theenterpriseleader.com ... shares of MacroGenics by 22.4% during the 2nd quarter. Bellevue Group AG now owns 7,376,026 shares of the biopharmaceutical company’s stock worth $198,121,000 after acquiring an additional 1,348,100 shares in the last quarter. RA Capital Management L.P. boosted its position in shares of MacroGenics by 20.5% during the 2nd quarter. RA Capital Management L.P. now owns 5,943,594 shares of the biopharmaceutical company’s stock worth $159,645,000 after acquiring an ...
12/22/2021 The Most Active Biotech Venture Investors in 2021 – Crunchbase News crunchbase.com ... and more.But two of those investment firms have emerged as major leaders, not only in the number of biotech funding rounds led, but also in overall dollars invested into the industry. Boston-based RA Capital Management and New York-based OrbiMed ranked first and second, respectively, on the two lists compiled using Crunchbase data.Although the two firms emerged as leaders in the data, they still make up a ...
12/20/2021 Tasso, Found score $100M and more digital health fundings MobiHealthNews Photo courtesy of Tasso/Business WireTasso , maker of a device for at-home blood collection, has raised $100 million in Series B financing.The round was led by RA Capital Management , with participation from the D.E. Shaw group, Senvest, InCube, SVB Innovation Fund, Foresite Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai and Merck GHIF.The latest financing builds upon a $17 million Series A from last year and ...
12/16/2021 malvern-online.com ... A financing that will allow the company to expand manufacturing of its flagship NX One platform as well as build its commercialization capabilities and pipeline to meet surging demand. The financing was led by RA Capital Management with participation by Section 32 as well as previous investors. The company also announced the appointment of William Rhodes to the Board of Directors.“Flow cytometry and cell sorting are tremendously valuable techniques ...
12/14/2021 Emergence Therapeutics Secures €87M in Series A Financing finsmes.com Emergence Therapeutics AG , a Duisburg, Germany-based biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers, closed an €87m series A financing round.The round was led by Pontifax Venture Capital and includes RA Capital Management , OrbiMed Advisors, Surveyor Capital (a Citadel company) and Hadean Ventures as new investors as well as existing investors Kurma Partners, NRW.BANK, High-Tech Gründerfonds, Gründerfonds Ruhr and ...
12/10/2021 Freenome Lands $300 Million Series D for Early Cancer Detection svdaily.com SOUTH SAN FRANCISCO — Freenome, a privately held biotech company, has landed a Series D funding of $300 million. This brings the company’s total financing to over $800 million since the company was founded in 2014.This round was led by Perceptive Advisors and RA Capital Management , joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society’s BrightEdge Ventures, Artis Ventures, Bain Capital Life ...
12/8/2021 Analysis: Top Biotech VC Investors in 2021 Based on Investments at IPO Business Insider ... Eighteen firms held shares worth $400 million or more in biotech companies that went public this year. Six top firms held more than $1 billion in equity: Arch Venture Partners, Novo Holdings, Flagship Pioneering, RA Capital Management , Perceptive Advisors, and SoftBank.Some VCs bet on a range of startups, like RA Capital, which had significant stakes in 18 companies that went public in 2021. Other firms focused on venture creation ...
12/7/2021 Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection PR Newswire ... Series D funding of $300 million . This brings the company's total financing to over $800 million since the company was founded in 2014.This round of financing was led by investors Perceptive Advisors and RA Capital Management , joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management ...
12/7/2021 Freenome Raises $300M in Series D Financing precisiononcologynews.com ... a prospective registrational study .It will also help speed the expansion of the firm's multiomic platform to other cancer types , such as pancreatic cancer , Freenome said.The round was led by Perceptive Advisors and RA Capital Management , who were joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management ...
12/7/2021 Freenome Raises $300M in Series D Financing genomeweb.com ... a prospective registrational study .It will also help speed the expansion of the firm's multiomic platform to other cancer types , such as pancreatic cancer , Freenome said.The round was led by Perceptive Advisors and RA Capital Management , who were joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management ...